[Final height (FH) in Turner syndrome (TS): experience of 76 cases followed at the Pediatric Endocrinology Unit, Hospital de Clinicas, Federal University of Paraná]

Arq Bras Endocrinol Metabol. 2011 Jun;55(5):318-25. doi: 10.1590/s0004-27302011000500004.
[Article in Portuguese]

Abstract

Objective: To report the final height (FH) of 76 patients with Turner syndrome (TS).

Materials and methods: Review of the files and calculation of z scores: of target height (TH), and FH according to NCHS/CDC/2000 and FH according to Lyon and cols.

Results: Patients were classified in three groups: A (n = 16), treatment with estrogens and progestogens; B (n = 21), treatment with oxandrolone (OX); C (n = 39), growth hormone (GH) plus OX. The z score of TH was not different among the groups and z score of FH was not different between A e B. Z score of FH of group C was greater than the other groups, > 2SDS of Lyon's curve and fitted on the 3(rd) percentile of NCHS/CDC. Multiple regression analysis showed type of treatment (p < 0.001) and maternal height (p = 0.02) as most influencing factors on FH.

Conclusion: GH plus OX and maternal height contributed significantly to enhance FH of TS patients.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adolescent
  • Age Determination by Skeleton
  • Androgens / therapeutic use*
  • Body Height / drug effects*
  • Child
  • Child, Preschool
  • Estrogens / therapeutic use*
  • Female
  • Follow-Up Studies
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Oxandrolone / therapeutic use
  • Progestins / therapeutic use*
  • Puberty / physiology
  • Regression Analysis
  • Treatment Outcome
  • Turner Syndrome / diagnosis
  • Turner Syndrome / drug therapy*

Substances

  • Androgens
  • Estrogens
  • Progestins
  • Human Growth Hormone
  • Oxandrolone